Compare Abeona Therapeutics Inc (ABEO) vs Ares Capital Corporation (ARCC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ares Capital Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Ares Capital Corporation trades at $18.28 (market cap $13.26B). The key difference: Ares Capital Corporation is far larger — about 35.5× Abeona Therapeutics Inc's market cap, and Ares Capital Corporation pays a 10.4% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ARCC | |
|---|---|---|
Market Cap | $373.32M | $13.26B |
Sector | Health | Financials |
52-Week High | $7.23 | $23.25 |
52-Week Low | $4.17 | $17.45 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 10.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARCC trades at $18.47, down 1.39% on the day, near its consensus low price target of $18.50. The stock shows neutral technical signals with mixed moving averages and oscillators. Recent quarterly EPS results have missed expectations, though the company maintains a high net income margin of 84.5%. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income-focused strategies.
Outlook remains cautiously optimistic given strong analyst support (24 Buy, 8 Hold) and a $20.58 consensus target implying ~11% upside. Risks include earnings misses and revenue declines from $1.7B in 2024 to a projected $1.4B in 2026. The stock's P/E of 11.39 and P/B of 0.95 suggest reasonable valuation amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →
